Epigenetic Regulation of the E Prostanoid 2 Receptor Gene in Lung Fibroblasts

肺成纤维细胞中 E 类前列腺素 2 受体基因的表观遗传调控

• 批准号: 8054188
• 负责人: STEVEN K HUANG
• 金额: $ 13.37万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8054188
• 关键词: Accounting; Address; Adult; Alveolar Macrophages; Area; Attention; Bleomycin; Cell Line; Cells; Chromatin; Collagen; Commit; Communities; Critical Pathways; DNA Methylation; Data; Deacetylation; Defect; Deposition; Development; Development Plans; Diagnosis; Dinoprostone; Disease; Disease Progression; Dyspnea; Effector Cell; Elderly; Environment; Environmental Exposure; Epigenetic Process; Epithelial Cells; Etiology; Exhibits; Extracellular Matrix; Fetal Lung; Fibroblasts; Fibrosis; Figs - dietary; Five-Year Plans; Functional disorder; Future; Gases; Gene Expression; Genes; Hamman-Rich syndrome; Histone Acetylation; Histone Deacetylation; Human; Instruction; Knowledge; Lead; Life Expectancy; Lung; Lung diseases; Malignant Neoplasms; Mediator of activation protein; Mentors; Mentorship; Metabolism; Methylation; Michigan; Modeling; Modification; Mus; Neuroblastoma; Organ; Pathogenesis; Pathologic; Pathology; Patients; Pattern; Physicians; Physiology; Play; Principal Investigator; Prostaglandin-Endoperoxide Synthase; Prostaglandins; Pulmonary Fibrosis; Receptor Gene; Records; Regulation; Research; Research Project Grants; Resistance; Respiratory Failure; Role; Scientist; Signal Transduction; Symptoms; Testing; Therapeutic; Time; Training; Transforming Growth Factors; Universities; base; career; career development; effective therapy; experience; indium-bleomycin; insight; lipid mediator; mouse model; neoplastic cell; outcome forecast; professor; prostaglandin EP2 receptor; receptor; receptor expression; response; skills; symposium

DESCRIPTION (provided by applicant): The applicant is committed to developing a career as a successful physician-scientist and has created a career development plan described in this proposal that will allow him to do so. The central component of this five-year plan is the research project outlined below. In addition, the applicant will benefit from the mentorship of Dr. Marc Peters-Golden (primary) and Dr. Bruce Richardson (co-mentor), both accomplished senior professors with extensive and successful track records for mentoring. Formal coursework, seminars, and conference participation are included in this plan. This plan is further enhanced by the outstanding research and mentoring environment that exists at the University of Michigan. Idiopathic pulmonary fibrosis (IPF) is a devastating disease with limited effective therapies. Abnormal fibroproliferation is a key pathobiological hallmark. Prostaglandin (PG) E2 is a lipid mediator that potently inhibits fibroblasts, the main effector cell in fibrotic responses. The applicant has recently discovered that fibroblasts from some patients with IPF are resistant to PGE2 suppression, and that this is due to deficiency of the E prostanoid (EP) 2 receptor. This finding parallels observations made in the bleomycin mouse model of pulmonary fibrosis. What is unclear is how EP2 expression is lost in these cells. Epigenetic changes, which are covalent modifications to DMA and chromatin, are important in regulating gene expression, and are increasingly recognized to be important in disease. Preliminary data suggest that epigenetic mechanisms may be responsible for loss of EP2 expression and impaired PGE2 responsiveness in fibrotic fibroblasts. To test this hypothesis, we will study lung fibroblasts from cell lines, patients with DIP, and from mice treated with bleomycin. Our Specific Aims will be to address the role of 1) DMA methylation and 2) histone deacetylation in regulating EP2 receptor expression and PGE2 responses in normal lung fibroblasts. We will then study how DMA methylation and/or histone deacetylation may be responsible for EP2 deficiency/PGE2 resistance in fibroblasts from 3) bleomycin-treated mice and 4) patients with IPF. The applicant will build upon his productive training experience by acquiring new scientific knowledge and research skills, particularly in the area of epigenetics, a field that has generated significant enthusiasm within the scientific community. Successful completion of the outlined studies will provide new insight into pathogenic mechanisms of pulmonary fibrosis and provide the applicant with the skills to achieve academic independence in an exciting and important research niche. RELEVANCE (See instructions): Idiopathic pulmonary fibrosis is a devastating lung disease with a poor prognosis and little effective therapy. The research proposed in this plan seeks to better understand the pathogenesis of pulmonary fibrosis which may lead to the development of better therapeutic strategies against this deadly disease.

描述（由申请人提供）：申请人致力于发展职业生涯作为一个成功的物理学家，科学家，并已创建了职业发展计划中所描述的这一建议，将允许他这样做。该五年计划的核心组成部分是下文概述的研究项目。此外，申请人将受益于Marc Peters-Golden博士（初级）和布鲁斯理查森博士（共同导师）的指导，他们都是有成就的资深教授，拥有广泛而成功的指导记录。正式的课程，研讨会和会议参与包括在这个计划。这一计划进一步加强了密歇根大学优秀的研究和指导环境。特发性肺纤维化（IPF）是一种严重的疾病，有效的治疗方法有限。异常纤维增生是一个关键的病理生物学标志。前列腺素（PG）E2是一种脂质介质，可有效抑制纤维化反应中的主要效应细胞成纤维细胞。申请人最近发现，来自一些IPF患者的成纤维细胞对PGE 2抑制具有抗性，并且这是由于E前列腺素类（EP）2受体的缺陷。这一发现与博莱霉素小鼠肺纤维化模型中的观察结果相似。目前尚不清楚的是EP 2表达在这些细胞中是如何丢失的。表观遗传变化是对DNA和染色质的共价修饰，在调节基因表达方面很重要，并且越来越多地被认为在疾病中很重要。初步数据表明，表观遗传机制可能是负责的EP 2表达的损失和受损的PGE 2反应性纤维化成纤维细胞。为了验证这一假设，我们将研究来自细胞系、DIP患者和博来霉素治疗小鼠的肺成纤维细胞。我们的具体目标将是解决1）DMA甲基化和2）组蛋白去乙酰化在调节正常肺成纤维细胞中EP 2受体表达和PGE 2反应中的作用。然后，我们将研究DMA甲基化和/或组蛋白脱乙酰化如何导致3）博来霉素治疗的小鼠和4）IPF患者的成纤维细胞中EP 2缺陷/PGE 2耐药性。申请人将通过获得新的科学知识和研究技能，特别是在表观遗传学领域，这是一个在科学界产生巨大热情的领域，建立在他的生产培训经验。成功完成概述的研究将为肺纤维化的致病机制提供新的见解，并为申请人提供在令人兴奋和重要的研究领域实现学术独立的技能。相关性（见说明）：特发性肺纤维化是一种严重的肺部疾病，预后差，治疗效果差。该计划中提出的研究旨在更好地了解肺纤维化的发病机制，这可能导致针对这种致命疾病的更好治疗策略的发展。